Andrew Wardley

1997–2023 年に発表

61
論文数
18,477
被引用数
47
h 指数
61
i10 指数

被引用数

Andrew Wardley の年別被引用数1974 年: 被引用 2 件1993 年: 被引用 2 件1997 年: 被引用 1 件1998 年: 被引用 4 件1999 年: 被引用 4 件2000 年: 被引用 6 件2001 年: 被引用 4 件2002 年: 被引用 12 件2003 年: 被引用 9 件2004 年: 被引用 13 件2005 年: 被引用 21 件2006 年: 被引用 32 件2007 年: 被引用 52 件2008 年: 被引用 95 件2009 年: 被引用 112 件2010 年: 被引用 156 件2011 年: 被引用 229 件2012 年: 被引用 196 件2013 年: 被引用 198 件2014 年: 被引用 176 件2015 年: 被引用 179 件2016 年: 被引用 187 件2017 年: 被引用 172 件2018 年: 被引用 161 件2019 年: 被引用 388 件2020 年: 被引用 534 件2021 年: 被引用 582 件2022 年: 被引用 630 件2023 年: 被引用 505 件2024 年: 被引用 590 件2025 年: 被引用 319 件2026 年: 被引用 8 件1975〜1992 年は被引用が無いため表示していません1994〜1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,091 件、この内訳の 22.7%イギリス: 引用元論文 715 件、この内訳の 7.8%イタリア: 引用元論文 688 件、この内訳の 7.5%中国: 引用元論文 687 件、この内訳の 7.5%ドイツ: 引用元論文 467 件、この内訳の 5.1%フランス: 引用元論文 409 件、この内訳の 4.4%スペイン: 引用元論文 384 件、この内訳の 4.2%カナダ: 引用元論文 383 件、この内訳の 4.2%スイス: 引用元論文 288 件、この内訳の 3.1%ベルギー: 引用元論文 285 件、この内訳の 3.1%オーストラリア: 引用元論文 282 件、この内訳の 3.1%日本: 引用元論文 236 件、この内訳の 2.6%
0%22.7%その他 24.7%

分野

  • Medicine65.6%
  • Biochemistry, Genetics and Molecular Biology29.9%
  • Immunology and Microbiology1.1%
  • Engineering0.6%
  • Materials Science0.6%
  • Computer Science0.4%
  • その他1.8%

トピック

  • HER2/EGFR in Cancer Research9%
  • Breast Cancer Treatment Studies7.6%
  • Advanced Breast Cancer Therapies7.4%
  • PARP inhibition in cancer therapy4.7%
  • Cancer Treatment and Pharmacology4%
  • Cancer Genomics and Diagnostics4%
  • その他63.3%

共著者

全論文

検索で開く
  1. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 986

  2. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın ほか 68 名 - Annals of Oncology 2021 被引用: 729

  3. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , F. Raja, Peter Schmid, Andrew Tutt, René L. Roux, Susan Cleator - Annals of Oncology 2022 被引用: 191

  4. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 549

  5. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 352

  6. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , A. Shaw, H. Tovey, A. Gutin, Vandna Shah, Andrew Tutt, A. Grigoriadis, Levi Fox, J.S. Lanchbury - Nature Medicine 2018 被引用: 903

  7. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 被引用: 378

  8. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 261

  9. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

    著者: , , , , , , , , , , , , , , - The Lancet 2010 被引用: 1,636

  10. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 127

  11. Genomic profile of advanced breast cancer in circulating tumour DNA

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 95

  12. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 被引用: 44

  13. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

    著者: , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 850

  14. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gianfilippo Bertelli, Pascuala Garcı́a-Martı́nez, R. Andrés, Tatiana Barannikova, Sònia Servitja, Jacques Médioni, Saverio Cinieri, Juan Bayo, Santiago González, Bohuslav Melichar, Vicente Caranyana, Francesco Atzori, Mark Beresford, Steven T. F. Chan, Maria Luque-Cabal, Juan de la Haba-Rodríguez, Joachim Bischoff, Guzel Mukhametsina, Maria Cazzaniga, Daniele Generali, Andrew Wardley, Laura Cortesi, Luigi Cavanna, Mario Airoldi - JAMA Oncology 2021 被引用: 106

  15. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 887

  16. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2009 被引用: 663

  17. Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 351

  18. Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline C. Newby, Elmar Stickeler, Helen Tranter, Scott Nichol, Matthew Winter, Ludger Barthelmes, Andrew Wardley, Amitabha Chakrabarti, U. Barthakur, Denise Hrouda, Pippa J Riddle, Alan L. Stewart, Chiara Intrivici, Nawaz Walji, Laura Pettit, S.C. Lupton, Pamela Woodings, Sekharan Chandrasekharan, William Maxwell, Andrew Simmonds, Rakesh Mehra, Medy Tsalic, Girija Anand, R. Allerton, Ketan Shah, Dimitri Hadjiminas, JaneMaree Maher, A.S. Dhadda, Lubna Bhatt, Ramachandran Venkitaraman, Anup Vinayan, Amanda Taylor, M. Hatton, Elin Jones, Karen McAdam, Claudia Harding-Mackean, Mark Harries, S. H. Da Silva, Mojca Persic, Jayant S. Vaidya, Anne Rigg, Lynda Wyld, Hisham Hamed, Omar S Shujja-Ud-Din, Richard Webster, Duncan Wheatley, Mariam Jafri, Abdulla Alhasso, Shazza Rehman, Simon Waters, Judith Fraser, Richard L. Hayward, J. Abraham, Helen Passant, Judy W. King, Vanessa Pope, Anthony Skene, Lucy Scott, Majory K Maclennan, Daniel Rea, N C Levitt, Sarah Khan, A Hönig, Bettina Müller, Gerhard Deutsch, Claus Hanusch, Nadia Harbeck, Sabine Lemster, Thomas Klein, Toralf Reimer ほか 134 名 - JAMA Oncology 2021 被引用: 47

  19. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Cameron, Janet Dunn, Roshan Agarwal, Hafiz Algurafi, R. Allerton, Caroline Archer, Anne Armstrong, C. Bale, Lisa Barraclough, U. Barthakur, C. Bedi, Kim Benstead, David Bloomfield, Rebecca Bowen, Chris Bradley, Jane Brown, Mohammad Butt, Mark Churn, Susan Cleator, Joanne Cliff, Perric Crellin, Margaret Daly, Shiroma De Silva-Minor, A.S. Dhadda, Omar Din, Sue Down, Helena Earl, David Eaton, Andrew Eichholz, Daniel Epurescu, Chee Goh, Andrew Goodman, Robert Grieve, Maher Hadaki, Catherine Harper‐Wynne, Mark Harries, Larry Hayward, Alison Humphreys, Helen Innes, Mariam Jafri, A. Jegannathen, Muireann Kelleher, Hartmut Kristeleit, Daniela Lee, Susan Lupton, Carol MacGregor, Zafar Malik, Janine Mansi, Jennifer Marshall, Karen McAdam, Trevor McGolick, Rakesh Mehra, David Miles, Natasha Mithal, Charlotte Moss, Aian Moss, Mukesh Mukesh, Anthony Neal, D. Nelmes, Helen Neville-Webbe, Jacqueline C. Newby, Susan O'Reilly, Peter Ostler, Mojca Persic, Laura Pettit, Sanjay Raj, Fharat Raja, Daniel Rea, Catherine Reed, Anne Rigg ほか 17 名 - The Lancet 2019 被引用: 283

  20. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 被引用: 36

  21. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    著者: , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 269

  22. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

    著者: , , , , , , , , , , , , , , - The Lancet Oncology 2013 被引用: 211

  23. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xichun Hu, Rabab Gaafar, Hamdy Abdel Azeem, Christophe Perrin, Johannes Ettl, István Láng, Sunil Verma, Huiping Li, Étienne Brain, Oliver Hoffmann, Anna Cariello, Carlo Tondini, Taher Altwegeiri, Niklas Loman, Michael P. Lux, Antonio Frassoldati, Zeba Aziz, Fernando Palacios Salas, Joanna Streb, A Wroński, Salomón Menjón Beltrán, İrfan Çiçin, Peter Schmid, Robert Laing, Zhongsheng Tong, Katalin Boér, Balázs Juhász, Luca Gianni, Giuseppe Curigliano, Alejandro Juarez, Sneẑana Šušnjar, Erika Matos, Rüçhan Uslu, Hans Wildiers, Marcelo Cruz, Hugues Bourgeois, Raquel von Schumann, Salomon M. Stemmer, Flavia Morales Vásquez, Adriana Domínguez, Marek Z. Wojtukiewicz, Jasna Trifunović, José Juan Illarramendi, Laura García, Y. Izarzugaza Perón, María José Echarri, Natliia Voitko, Duncan Wheatley, Simon Waters, Richard de Boer, Guy Jérusalem, Véronique Cocquyt, Carlos H. Barrios, Lawrence Panasci, Johanna Mattson, Minna Tanner, M. Gozy, G. Vasilopoulos, János Révész, Luciano Latini, Cesare Gridelli, Jesus Miguel Lazaro, Antonio González, A. Barnadas Molins, Eduardo Martinez, Jesús Alarcón, Ana Arance, Leif Klint, Oleksiy Kovalyov, Richard D. Baird ほか 193 名 - Annals of Oncology 2019 被引用: 113

  24. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2007 被引用: 1,511